| Mavacoxib (Ref: CL386965) |
![]() Last updated: 16/09/2025 |
![]() |
(Not known by any other names) |
|
|
|
A non-steroidal anti-inflammatory drug (NSAID) used in veterinary medicine | |
|---|---|---|
|
Used for the treatment of pain and inflammation associated with degenerative joint disease | |
|
Dogs |
| Approval status |
|
Approved - usually available as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
|---|---|---|
|
Approved |
| Chemical structure |
|
None | |
|---|---|---|
|
C₁₆H₁₁F₄N₃O₂S | |
|
C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F | |
|
No data | |
|
TTZNQDOUNXBMJV-UHFFFAOYSA-N | |
|
InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25) | |
|
Yes |
|
|
| Common Name | Relationship | Link |
|---|---|---|
| mavacoxib | - | ![]() |
| General status |
|
Anti-inflammatory, Analgesic, Medicinal drug | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Unclassified substance | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Synthetic | ||||||||||||||
|
Inhibits cyclooxygenase (COX). | ||||||||||||||
|
[Prostaglandin G/H Synthase 2, Antagonist] | ||||||||||||||
|
170569-88-7 | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Musculo-skeletal system: Anti-inflammatory & anti-rheumatic products | ||||||||||||||
|
QM01AH92 | ||||||||||||||
|
No | ||||||||||||||
|
- | ||||||||||||||
|
385.3 | ||||||||||||||
|
- | ||||||||||||||
|
4-[5-4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide | ||||||||||||||
|
- | ||||||||||||||
|
|
||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
| Commercial |
|
|
|||
|---|---|---|---|---|
|
Current | |||
|
Early 2000s, discovered; 2008, first EU approvals; 2009, UK & EU market launch | |||
|
|
|||
|
|
|||
|
Usually supplied as chewable tablets | |||
|
The production of mavacoxib involves a multi-step synthetic process based around constructing its pyrazole-sulfonamide core. The synthesis begins with the reaction of 4-fluoroaniline and trifluoroacetyl chloride to form 4-fluoro-N-(trifluoromethyl)aniline, introducing key fluorinated groups. This intermediate is then reacted with chloroacetyl chloride under basic conditions to yield a chloroacetamide derivative. Cyclisation with pyrazole forms the central heterocyclic ring. The final step involves sulfonylation using sulfonyl chloride, which introduces the sulfonamide group and completes the synthesis of mavacoxib. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
|
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
| Degradation |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- | ||||||||||
| Soil adsorption and mobility |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
| Fate indices |
|
|
|
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - | |||||||||||||||||||||||||||
| Known metabolites |
None
|
|
| Terrestrial ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
> 500 | Q3 Q = Miscellaneous data from online sources Rat3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
| - | |||||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- |
|
- | - | - | ||||||
|
- | ||||||||||
| Aquatic ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - | ||||||||
|
|
| General |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
High (class III) | - | - | ||||||||
|
> 500 | Q3 Q = Miscellaneous data from online sources Rat3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Mavacoxib is excreted via bile | A5 A = EU regulatory and evaluation data as published by EC, EFSA (RAR, DAR & Conclusion dossiers), EMA (e.g. EU Annex III PIC DGD) (EU - Pesticides database; EFSA Scientific Publications ) 5 = Verified data used for regulatory purposes |
- | ||||||||
| Health issues |
|
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
No further information available | ||||||||||||||||||||||||||||
| Handling issues |
|
|
|||
|---|---|---|---|---|
|
No information available | |||
|
- | |||
|
Not listed (Not listed) | |||
|
- | |||
|
- | |||
|
- |
|
|
|
|
||
|---|---|---|---|
|
mavacoxib | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
| Record last updated: | 16/09/2025 |
| Contact: | aeru@herts.ac.uk |
| Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |
© Copyright University of Hertfordshire, 2006-2026. All Rights Reserved
Your use of this website and its various databases is subject to the terms detailed in the University of Hertfordshire’s copyright and IPR statement that can be found at https://www.herts.ac.uk/about-us/legal. In addition, your use of this website and its various databases is subject to the terms of this additional Copyright Statement and the database Conditions of use document. Unless explicitly stated otherwise, the content of this website and databases are owned and controlled by the University of Hertfordshire. Site content, including its selection and arrangement, is owned by the University of Hertfordshire and is protected by copyright and other laws. Except as otherwise expressly permitted under copyright law or within the database Conditions of Use document, the content of this site may not be copied, reproduced, republished, downloaded, posted, broadcast or transmitted in any way without first obtaining the University of Hertfordshire’s written permission. By using our databases the user is deemed to have agreed to comply with all of the terms and conditions as described above and within all relevant documentation.





